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Abstract
Bone morphogenetic protein (BMP) signaling is important in prostate development and prostate cancer (PCa) pro-
gression. However, because of the multiple effects of different BMPs, no final conclusions have been made as to
the role of BMPs in PCa. In our studies, we have focused on BMP-7 because it is involved in prostate morpho-
genesis, and its expression is regulated by androgens. The objective of our study was to determine BMP-7 expression
in PCa metastases and investigate the effects of BMP-7 on PCa cells. Our results show that BMP-7 is expressed in
metastatic PCa and its levels are increased in castration-resistant PCa versus androgen-dependent PCa, whereas
the expression of BMP-7 is decreased in primary PCa versus normal prostate. Our in vitro results show that BMP-7
inhibits proliferation of androgen-sensitive LNCaP cells, stimulates androgen receptor signaling, increases the
expression of differentiation-associated genes, and decreases the levels of some wingless-regulated transcripts.
Interestingly, these effects were not detected in C4-2 castration-resistant PCa cells. In vivo expression of BMP-7 in
castration-resistant C4-2 cells did not alter proliferation when these cells were grown subcutaneously, but their
growth was inhibited in the bone environment. In summary, our results show that BMP-7 is expressed at the highest
level in advanced castration-resistant PCa cells and that the inhibitory effects of BMP-7 are dependent on the dif-
ferentiation status of PCa cells and the tumor microenvironment. Further studies are needed to identify changes in
BMP-7 signaling that lead to the loss of its control of proliferation during PCa progression.
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Introduction
A major challenge in prostate cancer (PCa) biology is elucidating the
mechanisms of development of PCa and its progression to bone metas-
tases. Bonemorphogenetic proteins (BMPs) were originally characterized
as inducers of bone formation and later studies demonstrated their roles
in the regulation of cell growth and differentiation [1]. Multiple BMPs
and BMP receptors (BMPR) are expressed in normal prostate and PCa
[2–5]. Therefore, it is not surprising that BMPs are involved in the con-
trol of proliferation and differentiation of these cells. Alterations in
BMPs and BMPRs have been detected during prostatic development
and PCa progression, and numerous reports have been published, dem-
onstrating the effects of BMPs on PCa cells, including effects on pro-
liferation and invasiveness as well as growth in the bone in vivo [6–8].
We have shown that the effects of BMP-2 and BMP-4 on the growth of
PCa cells depend on the cells’ differentiation status [5]. However, at
present, no final conclusions can be made about the effects of specific
BMPs because the published results are inconsistent [6,8–11].
In the present study, we have focused our investigations on the
expression and effects of BMP-7 in PCa because BMP-7 is critical
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for prostate morphogenesis, is regulated by androgens in normal
prostate [12] and because high levels of BMP-7 are expressed in normal
prostate epithelium [4]. Furthermore, BMP-7 levels were reported to be
downregulated in primary PCa versus normal prostate epithelium [4].
Although BMP-7 messages have been detected in PCa bone metastases
[3], BMP-7 expression has been shown to increase in a PTEN-knockout
murine model of PCa [10], and increased copy numbers of BMP-7were
detected in PCa tumors and PCa skeletal metastases [3,13]. Studies dem-
onstrating the effects of BMP-7 on proliferation and invasiveness of PCa
cells were published, but similarly to other BMPs, opposing effects were
reported. BMP-7 was reported to increase the invasive potential of PCa
cells [14] and protect PCa cells from stress-induced apoptosis [10], but in
contrast, administration of BMP-7 was also shown to inhibit growth of
PC-3 bone metastases and inhibit epithelial-mesenchymal transition
(EMT) [9]. Furthermore, BMP-7 has also been shown to be instrumen-
tal in altering the tumor-stromal microenvironment. BMP-7 increased
the expression of SDF1 in prostatic stroma in a PTEN-knockout model
of PCa [15], and hepatocyte growth factor increased the expression of
BMP-7 in PCa cells [16]. This indicates a role for BMP-7 in the inter-
actions that occur between stroma and PCa cells and illustrates the ef-
fects of environment on BMP-7 expression.
Similar to PCa, BMP-7 is thought to play a role in breast cancer.
BMP-7 has been detected in breast cancer tissues and it was associ-
ated with bone metastases [17,18]; it influences proliferation, migra-
tion, and invasion of breast cancer cells [19]. BMP-7 also inhibits
estradiol-induced proliferation of breast cancer cells [20]. Despite
the discordant results defining the specific effects of BMP-7 in
PCa and breast cancers, published data underscore the important role
that BMP-7 plays in cancer development and metastasis.
Recent studies show that multiple signaling pathways are altered
during cancer progression and support the view that these alterations
involve the integration of cross talk between signaling pathways. It
has been well established that activities of nuclear hormone receptors
are SMAD-dependent. There are several reports demonstrating a
cross talk between transforming growth factor β and androgen recep-
tor (AR) signaling pathways [21,22]. Although there is only limited
information regarding cross talk between the BMP and AR signaling
pathways, BMP-7 is regulated by androgens [12], and recently, it has
been shown that SMAD1 interacts with AR and decreases AR tran-
scriptional activity in LNCaP cells [23].
Another signaling pathway, the wingless pathway (Wnt), interacts
with SMAD and AR signaling, and is important in the regulation of
proliferation and differentiation as well as in cancer progression
[24,25]. β-Catenin (β-cat) is an important coactivator of AR [26,27],
a regulator of SMAD signaling, and also a major player in Wnt signal-
ing that contributes to PCa cell growth and survival [28–30]. AR-
directed transcription has been shown to be affected by Wnt activity
[31,32], and ligand-dependent inhibition of the Wnt pathway by AR
has also been observed [33,34]. Furthermore, cross talk between BMP
and Wnt pathways has been documented [35,36].
The objective of our studies was to examine BMP-7 expression in
advanced PCa and to investigate the effects of BMP-7 on cross talk
among the SMAD, AR, and Wnt signaling pathways in PCa cells. Our
results demonstrate that BMP-7 expression is increased in castration-
resistant (CR) versus androgen-dependent (AD) PCa cells and that
BMP-7 is expressed in PCa metastases. Our results also show that
BMP-7 elicits differential effects on CR and ADPCa cells. BMP-7 inhib-
ited the growth of LNCaP cells, stimulated AR-mediated transcription in
these cells (that represent an earlier stage of PCa progression), and induced
differentiation of LNCaP cells. These effects were not observed in theC4-
2 CR PCa cells. Furthermore, our data demonstrate that the mechanisms
intrinsic to these effects involve alterations in cross talk between SMAD/
AR and Wnt signaling pathways. Finally, our in vivo results show that
despite no detectable effects of BMP-7 on proliferation of C4-2 cells
in vitro, BMP-7 decreased growth of these cells and increased AR-
mediated transcription when grown in the bone environment. Illustrat-
ing biologic activities in vitro may not predict those in vivo [37].
Materials and Methods
Cell Culture and Supplements
The LNCaP PCa cell line (ATCC, Manassas, VA), its CR sublines
C4-2 and C4-2B (UroCor, Oklahoma City, OK), CR PCa cells DU
145, PC-3 (ATCC), MDA PCa 2b (gift from Dr. Nora Navone), and
VCaP (gift from Dr. Kenneth Pienta) were maintained under stan-
dard tissue culture conditions in RPMI 1640 with 10% fetal bovine
serum (FBS). Tissue culture medium and supplements were obtained
from Invitrogen (Carlsbad, CA). Recombinant human BMP-7 was
purchased from R&D Systems (Minneapolis, MN).
Real-time Polymerase Chain Reaction
Total RNA was extracted from primary PCa and normal prostate
tissues, PCa cell lines (LNCaP, C4-2, C4-2B, PC-3, DU145, MDA
PCa 2b; control cells, and cells treated with BMP-7 for 3 days), and
from paired AD and CR PCa LuCaP xenografts (LuCaP 23.1, LuCaP
35, LuCaP 77, LuCaP 96), using STAT-60 (Tel-Test, Friendswood,
TX). First-strand complementary DNA (cDNA) was prepared using
the Advantage RT-for-PCR kit (BD Biosciences, Palo Alto, CA). Real-
time polymerase chain reaction (PCR) was performed on a Rotor-Gene
RG-3000 (Corbett Research, Sydney, Australia) using PlatinumQuanti-
tative PCR SuperMix-UDG reagent (Invitrogen) and SYBR Green 1
(Molecular Probes, Eugene, OR). PCR primers (Table 1) were designed
to span intron-exon boundaries. The PCR parameters were as we have
described previously [38]. Reactions were carried out in duplicate, and
expression levels were calculated from standard curves that were gener-
ated from a four-fold dilution of LNCaP cDNA (all standard curves had
R 2 values >0.99).
Immunohistochemistry
Forty-four fixed paraffin-embedded PCa metastases from the Uni-
versity of Washington “Tissue Acquisition Necropsy Program” were
used for immunohistochemical analyses. This program has been previ-
ously described and has received local institutional review board approval
[39]. All tissues were processed by fixation in 10% neutral-buffered
formalin (bone metastases were decalcified in 10% formic acid) and
embedded in paraffin. Five-micrometer sections of tissue were used,
and staining was performedwith antigen retrieval as previously described
[40] using a rabbit polyclonal anti-BMP-7 antibody (ab56023; Abcam,
Inc, Cambridge, MA) at a concentration of 4 μg/ml. Negative control
slideswere incubatedwith rabbit immunoglobulinG (Vector Laboratories,
Inc, Burlingame, CA) at the same concentration. Immunostaining was
assessed by a pathologist Dr. Xiaotun Zhang, using a quasi-continuous
BMP-7 score, created by multiplying each intensity level (0 for no stain,
1 for faint stain, 2 for strong, and 3 for intense stain) by the corresponding
percentage of cells in the slide staining at that intensity, and then summing
the results. The response variable for the analysis is the BMP-7 score.
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Immunocytochemistry
LNCaP and C4-2 cells were cultured on Lab-Tek Chamber Slides
(Nalge Nunc Naperville, IL). After treatment in phenol red–free RPMI
with 5% charcoal-stripped serum with or without BMP-7 (500 ng) for
48 hours, cells were fixed and incubated with mouse monoclonal anti–
human AR antibody (1:60; BioGenex, San Ramon, CA) or rabbit poly-
clonal anti–human β-cat antibody (5 μg/ml; Santa Cruz Biotechnology,
Inc, Santa Cruz, CA) and then with a goat–antimouse Alexa Fluor 546
and goat–anti-rabbit Alexa Fluor 488 both at a dilution of 1:400,
respectively, and mounted with ProlongGold antifade reagent with
4′,6-diamidino-2-phenylindole (Invitrogen).
Proliferation Studies
LNCaP (4000 cells per well) and C4-2 (3000 cells per well) were
seeded in 96-well plates in 100 μl of phenol red-free RPMI 1640
medium with 5% FBS. The following day, BMP-7 (R&D Systems)
was added (0, 100, 250, or 500 ng/ml). After 3 days, the effects on
proliferation were determined using the Quick Cell Proliferation
Assay (BioVision, Inc, Mountain View, CA) and by direct counting
of the cells by Trypan blue exclusion. Experiments were run in trip-
licate and repeated two to three times.
Whole-Cell Lysate, Nuclear, and Cytoplasmic
Protein Preparation
Whole-cell lysates and nuclear and cytoplasmic proteins were prepared
as we described previously [41]. Protein levels were determined using the
BioRad DC Protein Assay Kit (BioRad Laboratories, Hercules, CA).
Western Blot Analysis
Proteins were separated on SDS-PAGE and transferred to poly-
vinylidene fluoride membranes. Membranes were blocked with 5%
nonfat dried milk in TBST (15 mM Tris-HCl, pH 7.4, 0.9% NaCl,
and 0.05% Tween 20, pH 7.4) or with 5% BSA followed by blot
analysis with specified antibodies: mouse monoclonal anti–human AR
antibody (3:1000; BioGenex); rabbit polyclonal anti–human phospho-
SMAD1, 5, and 8 antibody (1:1000; Cell Signaling Technology, Inc,
Danvers, MA); mouse monoclonal anti–human β-cat (E-5, 1:5000);
rabbit polyclonal anti–human AR (C-19, 3:1000); and E-cadherin
(G-10, 3:1000) from Santa Cruz Biotechnology, Inc. To determine
BMP-7 expression in BMP-7–C4-2 cells, we used mouse monoclonal
anti–human BMP-7 antibody (MAB3541, 1:5000; R&D Systems). To
determine BMP-7 expression in PCa metastases, xenografts, and cell
lines, we used rabbit polyclonal anti–BMP-7 antibody (ab56023;
Abcam, Inc). To confirm uniform loading of protein, blots were re-
probed with rabbit polyclonal anti-GAPDH antibody (Ab9385,
1:1000; Abcam, Inc), rabbit polyclonal antiactin antibody (1:1000;
Sigma Chemical Co, St. Louis, MO) for cytosolic extracts or rabbit poly-
clonal anti–human histone 4 (H-97, 3:1000; Santa Cruz Biotechnology,
Inc) for nuclear extracts.
Immunoprecipitation
Five micrograms of rabbit polyclonal anti–human AR (C-19; Santa
Cruz Biotechnology, Inc) was prebound to 50 μl of Dynal Protein A
Dynabeads (Invitrogen). The primary antibody–bead complexes were
blocked and then incubated with ∼200 μg of nuclear extracts from
BMP-7–treated and control cells. Proteins were separated on an SDS-
PAGE gel and blotted as described previously. β-Catenin was detected
using a mouse monoclonal anti–human β-cat (E-5, 1:5000; Santa Cruz
Biotechnology, Inc).
Transient Transfections
An Amaxa Nucleofector II system (Amaxa Biosystems, Inc, Gaithers-
burg,MD)was used for the transfection of PCa cells using solutionVand
program T-27 according to the manufacturer’s directions. LNCaP and
C4-2 cells were transfectedwithARE [42,43], E-cadherin, andTOPflash
reporter plasmids (1 μg) and, if specified, with the effector plasmids
Table 1. Primer Sequences.
Gene Sequence Annealing (°C) Accession No. Amplicon (bp)
AR 5′ GGA CTT GTG CAT GCG GTA CTC A 65 NM_000044 178
3′ CCT GGC TTC CGC AAC TTA CAC
β-catenin 5′ CTG CAG AAA ATG GTT GCC TTG CTC A 69 NM_001904 215
3′ GCA GAC AGA TAG CAC CTT CAG CAC
BMP-7 5′ TGG CAG CAT CCA ATG AAC AAG ATC C 69 NM_001719 221
3′ TTC CTT TCG CAC AGA CAC CAA TGT G
BMPR-IA 5′ CAT TTG GGA GAT GGC TCG TCG TTG 69 NM_004329 234
3′ ATG CTG TGA GTC TGG AGG CTG GAT
BMPR-IB 5′ GTA TTG CTG ACC TGG GCC TG 66 NM_001203 174
3′ AGG CCA AAA CTA TAC ATG TCA GCC
BMPR-II 5′ GTG TGC TGA GGA AAG GAT GGC TGA 69 NM_033346 169
3′ GGG AGT TTT CAC ACG TTT CTT GAT CT
C-Myc 5′ CAC TGG AAC TTA CAA CAC CCG AGC 69 NM_002467 235
3′ ACC GAG TCG TAG TCG AGG TCA TAG
E-cadherin 5′ GGC GGA GAA GAG GAC CAG GAC TT 69 NM_004360 254
3′ AGA GAA TCA TAA GGC GGG GCT GTG
KLK2 5′ ATG TTG TGT GCT GGG CTC TGG AC 69 NM_005551 195
3′ GGT TGG CTG CGA TCC TGT CCT TG
PSA 5′ CCC CAG AAT CAC CCG AGC AG 65 NM_001648 160
3′ ACC AGA GGA GTT CTT GAC CCC AAA A
RPL13a 5′ CCT GGA GGA GAA GAG GAA AGA G 60 NM_012423 125
3′ TTG AGG ACC TCT GTG TAT TTG TCA A
Survivin 5′ GCT TCA TCC ACT GCC CCA CTG AG 65 NM_001168 150
3′ TTT TGT TCT TGG CTC TTT CTC TGT CC
Vimentin 5′ CCT TGA ACG CAA AGT GGA ATC 65 NM_003380.2 105
3′ GAC ATG CTG TTC CTG AAT CTG AG
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containing the open reading frame for β-cat (S33F), SMAD1, and AR
(1 μg or as specified). TK renilla-luciferase plasmid was transfected under
the same conditions to allow for normalization of transfection efficien-
cies. Cells were then plated in phenol red–free RPMI 1640 medium,
supplemented with 5% FBS and incubated for 48 hours. Cells were
lysed and subjected to a dual-luciferase assay according to the manu-
facturer’s recommendations (Promega,Madison,WI). Experiments were
performed in triplicate and repeated two to three times.
Stable Transfection of C4-2 Cells with BMP-7
C4-2 cells were transfected using the Amaxa Nucleofector II with
EcoRV linearized pcDNA3.1-V5-His-TOPO containing the ORF of
the human BMP-7 gene, which was amplified using forward GAGCCC-
GGAGCCCGGGTAGCGCGTA and reverse AGGTCTCACAA-
AAGGCAGTTGGTCT primers then sequenced. Transfected cells
were selected using 600 μg/ml G418 and maintained in 300 μg/ml
G418 (Invitrogen).
Alkaline Phosphatase Activity
Primary cultures of human osteoblasts (ScienCell, Carlsbad, CA)
were grown in osteoblast medium (ScienCell) and cocultured in trans-
well plates with pcDNA–C4-2, BMP-7–C4-2 cells or with 500 ng/ml
recombinant BMP-7 (R&D Systems). Alkaline phosphatase activity in
the cell lysate was determined using p-nitrophenyl-phosphate as a sub-
strate (Vector Laboratories, Inc) and calculated as ΔA450/mg protein.
C4-2 Subcutaneous and Intratibial Tumors
For subcutaneous tumor formation, 6-week-old male severe com-
bined immunodeficient (SCID) mice (Charles River Laboratories,
Tacoma, WA) were injected subcutaneously with 2 × 106 PCa cells
mixed with Matrigel (BD Biosciences, San Jose, CA). Two groups of
five animals each were used: 1) control pcDNA–C4-2 cells and 2)
BMP-7–C4-2 cells. Tumor volumes (TuV) were measured twice a
week and calculated using the formula L × H × W × 0.5326. Blood
samples were drawn from animals weekly for determination of serum
prostate-specific antigen (PSA) levels starting at day 20 after tumor
cell injection (IMx Total PSA Assay; Abbott Laboratories, Abbott
Park, IL). Animals were killed when tumors reached 1000 mm3 or
if animals were compromised.
For intratibial tumor formation, 6-week-old male SCID mice were
injected with 2 × 105 PCa cells into the tibiae as we described pre-
viously [44]. Two groups of 10 animals each were used: 1) pcDNA–
C4-2 and 2) BMP-7–C4-2. Blood samples were drawn from animals
weekly for determination of serum PSA levels starting at week 2 after
tumor cell injection to monitor tumor growth. Animals were killed
9 weeks after tumor cell injection. Bone mineral density (BMD) was
measured using a PIXImus Lunar densitometer (GE Healthcare,
Waukesha, WI), and radiographs were obtained using a Faxitron
Specimen Radiography System, Model MX-20 (Faxitron x-ray Corp,
Wheeling, IL) just before sacrifice. After sacrifice, the tibiae with tu-
mor were harvested and embedded in methyl methacrylate for bone
histomorphometry (BHM).
Bone Histomorphometry
Six-micrometer longitudinal sections of undecalcified tibiae em-
bedded in methacrylate and stained with Goldner trichrome were
used [45]. BHM analysis was performed on the whole longitudinal
section in the middle of the tibia (n = 5 per group). The bone volume
(BV), TuV, and tissue volume (TV) were measured using Bioquant
Software (Bioquant Image Analysis Corp, Nashville, TN).
Data Analyses
Statistical analyses of the results were performed using Prism soft-
ware (Prism GraphPad, San Diego, CA). Significance of differences was
evaluated using paired and unpaired Student’s t tests as appropriate,
except for immunohistochemical analysis where we used the Wilcoxon
signed-rank test, P values ≤ .05 indicating statistical significance.
Results
BMP-7 Messenger RNA Levels Are Altered during
PCa Progression
It has been reported that levels of BMP-7 messages and protein
are decreased in PCa versus normal prostate [4,46]. However, ampli-
fication of the BMP-7 gene was detected in PCa [13] and increased
levels of BMP-7 were associated with PCa in PTEN conditional
knockout mice [10,47]. Therefore, in our first studies, we set out
to examine BMP-7 levels in PCa and normal prostatic epithelium
and in PCa metastases. We used matched pairs of microdissected
normal epithelium and PCa cells from the same patients, obtained
at radical prostatectomy (n = 13). Our data showed that levels of
BMP-7 messenger RNA (mRNA) were lower in primary PCa versus
NP in all pairs examined (−33.1 ± 10.1% [mean ± SEM], P = .0001),
which is in agreement with published data. Next, we examined the
levels of BMP-7 in AD versus CR PCa cells because BMP-7 expres-
sion is regulated by androgens in normal prostate epithelial cells [12],
and PCa progression is associated with alterations in AR signaling. To
do this, we used the LNCaP/C4-2/C4-2B progression model and
four pairs of AD and CR PCa xenografts. In the LNCaP/C4-2/
C4-2B model of PCa progression, levels of BMP-7 mRNA were low-
est in the androgen-sensitive LNCaP cells, and higher levels were de-
tected in the CR C4-2, C4-2B cells (Figure 1A). We then examined
the expression of BMP-7 in PCa paired AD and CR xenografts
established in our laboratory (LuCaP 77, LuCaP 96, LuCaP 23.1,
and LuCaP 35). BMP-7 messages were detected in all of the AD
xenografts: in LuCaP 96 that was established from primary PCa as
well as in LuCaP 77, LuCaP 23.1, and LuCaP 35 that were estab-
lished from PCa metastases. When we compared levels of BMP-7
mRNA in the AD and CR sublines, BMP-7 mRNA levels were in-
creased in all CR-PCa xenograft lines (Figure 1B). The LuCaP 23.1
xenograft had the smallest relative increase in BMP-7 mRNA levels.
However, it should be noted that although it is not apparent from
Figure 1B, LuCaP 23.1 expresses high levels of BMP-7 mRNA in
AD cells (data not shown).
BMP-7 Protein Is Highly Expressed in PCa Metastases
BMP-7 mRNA levels are decreased in primary PCa versus NP, but
our data from the PCa xenografts suggested increased expression in
CR versus AD PCa. Therefore, it was important to determine whether
BMP-7 is expressed in patient samples of advanced PCa, to establish
clinical relevance of this factor to advanced disease. In one report,
BMP-7mRNAwas detected in PCa bonemetastases [3], but no studies
have been published about the levels of BMP-7 protein in PCa bone
metastases. In our studies, Western blot results showed that BMP-7 is
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expressed in human samples of NP, primary PCa, and in PCa metas-
tases. The BMP-7 antibody in used in these analyses detects one major
band of expected molecular weight, indicating high specificity of this
antibody (data not shown). We therefore used this antibody for the im-
munohistochemical evaluation of BMP-7 expression in NP, primary
PCa, and PCa metastases. We used tissues from NP (n = 12; from
12 patients), primary PCa (n = 12; from 12 patients), soft tissue me-
tastases (n = 20; from 15 patients), and PCa bone metastases (n = 14;
from 11 patients) from patients who died of advanced PCa. These spe-
cimens were acquired under our “Tissue Acquisition Necropsy Pro-
gram” [39,48]. BMP-7 was detected in all metastatic samples and
was predominantly localized in the cytoplasm of the tumor cells with
occasional nuclear staining. Nuclear BMP-7 expression has been previ-
ously observed in breast tumors [46].
The BMP-7 scores in the epithelial portion of the tissues examined
were as follows (mean ± SD): NP = 123.7 ± 50.5, range = 54-230;
primary PCa = 123.1 ± 63.4, range = 10-210; soft tissue metastasis =
161.6 ± 93, range = 5-300; and bone metastasis = 191.6 ± 79.7,
range = 10-300. The metastases scored higher than NP and primary
PCa; however, there was a considerable range of staining within each
of the groups. There were no significant differences between the cyto-
plasmic BMP-7 score between NP and primary PCa (P = 1) or bone
and soft tissue metastases (P = .7896). The only significant differ-
ence between groups was between NP and bone metastases (P =
.0407). Representative examples of BMP-7 immunoreactivity in NP,
PCa, and metastasis are shown in Figure 1C . The large ranges in stain-
ing activity in these 58 clinical specimens illustrate yet again the hetero-
geneity of target protein expression in NP, primary PCa, and PCa
metastases [39].
Effect of BMP-7 on PCa Cell Proliferation and AR
Transcriptional Activity
BMP-7 regulates growth and differentiation of epithelium, and be-
cause our studies showed protein as well as gene expression in normal
prostate epithelium, primary PCa, and PCa metastases, we next eval-
uated the effects of BMP-7 on PCa cell proliferation. We found that
BMP-7 inhibits proliferation of the AD, AR-expressing LNCaP cells
but not the CR PC-3 cells (Figure 2A). These results are concordant
with our previous data showing that BMP-2 and BMP-4 inhibited
growth of LNCaP cells, whereas PC-3 cells were not affected [5].
One of the obvious differences between LNCaP and PC-3 cells is
the lack of AR expression in PC-3 cells. Thus, we next investigated
whether AR is critical for the inhibition of LNCaP proliferation. For
these experiments, we used the C4-2 and C4-2B sublines of LNCaP
Figure 1. BMP-7 is expressed in PCa cell lines, xenografts, and metastases. (A) Expression of BMP-7 mRNA in PCa cell lines. (B) Ex-
pression of BMP-7 mRNA in four AD and corresponding CR LuCaP xenografts. Results are plotted as mean ± SEM. *CR significant from
AD (P< .05; n = 2-6). (C) Representative samples of BMP-7 expression in NP (a and f), PCa (b and g), and bone (c and h), lymph (d and i),
and lung (e and j) PCa metastases. Original magnification, ×200.
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that express AR but are CR; only LNCaP cells were inhibited by
BMP-7 (Figure 2, A and B). In these experiments, proliferation of
C4-2 cells was actually slightly increased as determined by the alter-
ation of mitochondrial activity; however, the manual cell count did
not confirm this phenomenon. In the next set of experiments, we
examined whether AR expression is critical for BMP-7 inhibition
of LNCaP proliferation. LNCaP cells were transiently transfected
with a control small interfering RNA (siRNA) or AR siRNA and
treated with BMP-7. Real-time PCR showed that levels of AR
dropped to ∼20% after AR siRNA transfection versus control siRNA
transfected LNCaP cells. LNCaP cells with significantly decreased
levels of AR showed no inhibition of proliferation. This demonstrates
that the AR is required for BMP-7 inhibition of LNCaP proliferation.
These results together clearly indicate that AR alone is not sufficient to
Figure 2. Effect of BMP-7 on cell proliferation and AR activity in LNCaP and C4-2 cells in vitro. (A) Effect of BMP-7 (500 ng) on prolif-
eration in LNCaP, C4-2, C4-2B, and PC-3 cells. (B) Effect of increasing doses of BMP-7 on proliferation in LNCaP and C4-2 cells. (C) Effect
of silencing AR on proliferation in LNCaP cells in the presence or absence of BMP-7 (500 ng). (D) Expression of AR mRNA in four AD and
corresponding CR LuCaP xenografts. (E) Altered expression of phosphorylated Smad1 (P-Smad1) in LNCaP and C4-2 cells in the pres-
ence or absence of BMP-7 (500 ng) for 3 days. Histone H4 (H4) was blotted as a control. (F) Western analysis of nuclear, cytosolic, and
total AR (with GAPDH as control for total AR expression) in LNCaP and C4-2 cells with or without BMP-7 (500 ng) for 3 days.
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inhibit proliferation in response to BMP-7 of C4-2 and C4-2B cells
but that AR is a critical player in the BMP-7 inhibition of proliferation
of LNCaP cells (Figure 2C ). We hypothesize that alteration in AR sig-
naling in CR PCa cells makes these cells resistant to inhibition of pro-
liferation by BMP-7. These data are further supported by the fact that
the expression of AR in the CR LuCaP xenografts, similar to BMP-7,
is significantly increased when compared with their AD counterparts
(Figure 2D). To better understand the mechanisms behind the dif-
ferential effects of BMP-7 on PCa cells and the role of AR in this in-
hibition, we chose to further examine the effects of BMP-7 on LNCaP
and C4-2 cells, as the pair of the most closely related cell lines that
express AR but exhibit different responses to BMP-7. Published results
indicate that PCa cells express BMP receptors and our PCR data are
concordant with these results (data not shown) [47]. We confirmed
that LNCaP and C4-2 cells express SMAD1 and that SMAD1 is
phosphorylated in both LNCaP and C4-2 cells after treatment with
BMP-7, demonstrating the presence of active BMP signaling in both
cell lines (Figure 2E ).
Effects of BMP-7 on AR Levels and
AR-Mediated Transcription
Our results show that AR expression in LNCaP cells is critical for
BMP-7 inhibition of proliferation. Because AR is involved in regulating
PCa proliferation and changes in AR signaling occur in CR PCa versus
AD PCa, we decided to investigate whether BMP-7 exhibits differen-
tial effects on AR-mediated signaling. Western blot analysis showed
that while BMP-7 did not alter total levels of AR, it resulted in an ac-
cumulation of AR in the nucleus and a concomitant decrease in the
cytoplasm of LNCaP cells, whereas no alteration of cellular distri-
bution was detected in C4-2 cells where AR was mainly nuclear in
the presence or absence of BMP-7 (Figure 2F ). Immunofluorescence
also showed that AR, which is mainly localized in the cytoplasm in
LNCaP cells in the absence of androgens, translocates to the nucleus
on BMP-7 treatment, similarly to treatment with dihydrotestosterone
(DHT). In contrast, in C4-2 cells, AR is already localized mainly in
the nuclei in the absence of androgens, and the addition of BMP-7
or DHT do not cause any visible changes (Figure 3, A and B ). Be-
cause BMP-7 increased nuclear localization of AR in LNCaP cells,
we next evaluated the effects of BMP-7 on AR-mediated transcrip-
tion using a synthetic ARE reporter construct. BMP-7 increased AR
transcriptional activity in LNCaP cells in a concentration-dependent
fashion, whereas no increases were detected in C4-2 cells (Figure 3C ).
To confirm that the lack of AR signaling in response to BMP-7 is not
cell line–specific, we examined AR-mediated transcription in two
other CR-PCa lines, PC-3 cells transfected to express AR and VCaP
cells. BMP-7 did not increase AR-mediated transcription in PC-3
cells transfected to express AR (P = .9145) and VCaP cells (P =
.2170), further supporting the hypothesis that BMP-7 does not alter
Figure 3. BMP-7 alters AR localization and transcriptional activity in LNCaP cells. (A) Immunohistochemical analysis of the AR in LNCaP
and C4-2 cells cultured in charcoal-stripped serum with or without BMP-7 (500 ng) for 2 days. (B) Immunohistochemical analysis of the
AR in LNCaP and C4-2 cells cultured in charcoal-stripped serum with or without DHT (10 nM) for 2 days. (C) Effect of BMP-7 on AR
activation in LNCaP and C4-2 cells. (D) Altered mRNA expression of markers of epithelial differentiation and Wnt-regulated genes in
LNCaP and C4-2 cells by BMP-7 (500 ng) for 3 days. Results are plotted as mean ± SEM. *Significant from control.
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AR-mediated transcription in CR-PCa cells. In an effort to further sub-
stantiate our assertion that BMP-7 alters AR-mediated transcription
in LNCaP cells, we extended our studies to examine the effects of
BMP-7 on PSA levels in the medium of LNCaP and C4-2 cells. Levels
of PSA (ng/ml/105 cells) were increased 3.02 ± 0.08-fold in the medi-
um of BMP-7–treated LNCaP cells versus parental cells, whereas no
significant change (1.16 ± 0.39) was observed in C4-2 cells (P =
.0013). Additional evidence that BMP-7 alters AR-mediated transcrip-
tional activity was provided by real-time PCR. Increased levels of AR
mRNA and endogenous AR-regulated genes including PSA and human
kalikrein-2 (KLK2) mRNA were detected in LNCaP cells, but not in
C4-2 cells, on BMP-7 treatment (Figure 3D).
SMAD1 Increases AR Activity in LNCaP Cells
It has been reported that SMAD1 associates with AR [23]. To dem-
onstrate that SMAD1 is instrumental in increasing AR-transcriptional
activity in LNCaP cells, we overexpressed SMAD1 in these cells.
SMAD1overexpression caused a 5.4 ± 0.7-fold increase in AR transcrip-
tional activity versus control cells (P = .038; Figure 4A).
Figure 4. BMP-7 alters AR interactions with β-cat in LNCaP cells. (A) Luciferase assay to determine the effect of Smad1 and β-cat on ARE
binding and promoter activation in LNCaP cells. (B) Expression of β-cat and AR in LNCaP and C4-2 cells with or without BMP-7 (500 ng)
for 3 days. GAPDH was blotted as a control (the same blot as in Figure 2F ). (C) Immunoprecipitation of AR/β-cat complexes in the
nucleus of LNCaP and C4-2 cells with or without BMP-7 (500 ng) for 3 days. Nuclear β-cat was blotted as a control. (D) Expression
of E-cadherin in LNCaP and C4-2 cells with or without BMP-7 (500 ng) for 3 days. GAPDH was blotted as a control. (E) Immunohisto-
chemical analysis of β-cat in LNCaP and C4-2 cells cultured in charcoal-stripped serum with or without BMP-7 (500 ng) for 2 days.
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BMP-7 Alters AR Interactions with β-Cat in LNCaP Cells
β-Catenin is a transcription cofactor that is involved in regulating
AR as well as SMAD signaling. SMAD1 overexpression increases AR
transcriptional activity in the presence of β-cat over that of β-cat
alone (Figure 4A). Therefore, we next examined whether the levels
of β-cat or its interaction with AR are altered in LNCaP and C4-2
cells on BMP-7 treatment. Real-time PCR results showed that BMP-
7 treatment resulted in significant increases of levels of β-cat in
LNCaP cells 1.00 ± 0.018 (mean ± SEM; Control) versus 1.72 ±
0.025 (BMP-7; P = .0018) but not in C4-2 cells (P = .9) in the ab-
sence of androgens. Similarly, Western analysis showed a subtle in-
crease in β-cat protein levels in LNCaP but not in C4-2 cells after
BMP-7 treatment (Figure 4B). In contrast to our expectations, when
we examined the association between AR and β-cat, our results
showed that BMP-7 treatment decreased the association of AR with
β-cat in LNCaP cells (Figure 4C ). Next, we looked at the localization
of β-cat in LNCaP and C4-2 cells after BMP-7 treatment in the ab-
sence of androgens. The immunofluorescent staining showed that
there is increased membrane-bound β-cat in the LNCaP cells but
not C4-2 cells after BMP-7 treatment (Figure 4E ). These results sug-
gest that alterations in protein levels as well as protein-protein asso-
ciations among AR, SMAD1, and β-cat may be a significant
mechanism whereby biologically relevant cross talk occurs between
the SMAD1 and AR pathways.
Cross talk between the AR and Wnt Pathway in PCa Cells and
BMP-7 Effects on Wnt-Regulated Genes
In a complex signaling network, it is inevitable that an alteration
in one pathway affects other pathways. It has been suggested that
cross talk between AR and Wnt signaling exists in PCa cells
[24,25,33,49]. Activation of the Wnt pathway is associated with can-
cer proliferation and progression [25], and increased levels of Wnts
and β-cat have been detected in clinical samples of PCa
[28,29,34,50]. To confirm that there is cross talk between AR and
Wnt signaling in LNCaP cells, we used a reporter assay with an
ARE-luc and TOPflash reporter. TOPflash activity is below the limit
of detection in LNCaP cells; therefore, we transfected these cells with
constitutively active β-cat (S33F) to stimulate Wnt activity. Our re-
sults show that DHT, while stimulating AR-mediated transcription,
caused inhibition of Wnt signaling (Figure 5A). In addition, AR ex-
pression in PC-3 cells inhibited Wnt signaling and abolishing AR
using AR siRNA in LNCaP cells stimulated WNT signaling (Fig-
ure 5, B and C ). These data demonstrate that a competition exists
between AR and Wnt signaling in PCa cells. For that reason and be-
cause BMP-7 increased AR-mediated transcription in LNCaP cells,
we investigated whether BMP-7 also alters Wnt signaling in PCa
cells. Because the Wnt transcriptional activity in PCa cells without
the overexpression of β-cat was below the limit of the reporter assay,
we used real-time PCR to examine the effects of BMP-7 on WNT-
regulated genes c-Myc and survivin. In our real-time studies, de-
scribed previously, our data show that BMP-7 treatment decreased
the levels of c-Myc and survivin transcripts in LNCaP cells, with
no significant changes in C4-2 cells (Figure 3D).
Effect of BMP-7 on E-cadherin and Vimentin Expression in
PCa Cells
The increases in AR-mediated transcription and decreases in the
Wnt-regulated genes suggest that BMP-7 may stimulate differentia-
tion of LNCaP cells. It is well documented that BMP-7 plays a role
in epithelial differentiation and that alterations in differentiation and
EMT are associated with tumor progression and metastasis in cancer.
EMT is accompanied by decreases in the expression of E-cadherin, a
marker of epithelial cells, and by increases in the expression of vimen-
tin, a marker of mesenchymal cells [51]. To further investigate the
mechanisms of effects of BMP-7 on the differentiation status of
PCa cells, we showed that there is a trend toward increased levels
of E-cadherin mRNA and decreased levels of vimentin mRNA levels
in LNCaP cells after BMP-7 treatment but not in C4-2 cells
(Figure 3D). To further support these data, we showed that BMP-
7 treatment increased the levels of E-cadherin protein in LNCaP cells
and decreased E-cadherin protein levels in the CR C4-2 cells
(Figure 4D). As described earlier, β-cat localized to the membrane
in BMP-7–treated LNCaP cells, possibly interacting with E-cadherin,
promoting a more differentiated epithelial phenotype.
The Characterization of C4-2 Overexpressing BMP-7
(BMP-7–C4-2) Cells
The finding that in vitro more differentiated LNCaP cells are in-
hibited by BMP-7 whereas CR-PCa cells are not affected suggests
that there are alterations in the cross talk between of BMP and AR
signaling during PCa progression. Although the in vitro data are
helpful in increasing our understanding of PCa biology, it is impor-
tant to confirm these findings in vivo and particularly in the bone
environment. Therefore, to substantiate our claim that BMP-7 sig-
naling is altered in CR PCa, resulting in loss of growth control, we
generated C4-2 cells overexpressing BMP-7 and evaluated the effects
of BMP-7 on the growth of CR C4-2 cells in vivo subcutaneously
and in the bone environment.
Before growing these cells in vivo, we characterized them in vitro.
Characterization of the BMP-7–C4-2 cells showed that these cells
expressed ∼60-fold more BMP-7 mRNA when compared with con-
trol pcDNA–C4-2 cells (Figure 6A ) and that BMP-7 protein is se-
creted into the medium of BMP-7–C4-2 cells, whereas no BMP-7
was detected in the control cell medium (Figure 6B ). Overexpression
of BMP-7 in BMP-7–C4-2 cells did not significantly alter prolifera-
tion versus pcDNA–C4-2 cells (Figure 6C ), but lower levels of PSA
were detected in the medium of the BMP-7–C4-2 cells (Figure 6D)
similarly to treatment with recombinant BMP-7 (Figure 3D). To
ensure that the expressed and secreted BMP-7 possessed biologic
activity, we examined the effects of conditioned medium from BMP-
7–C4-2 and pcDNA–C4-2 cells on alkaline phosphatase activity in
human osteoblasts. Conditioned medium from BMP-7–C4-2 cells in-
creased alkaline phosphatase activity in osteoblasts relative to control
pcDNA–C4-2 cells, demonstrating that the secreted BMP-7 is biolog-
ically active (Figure 6E ).
Effect of BMP-7 Overexpression in C4-2 In Vivo
Subcutaneous tumors. The take rate of subcutaneous C4-2 tumors
was not altered by BMP-7 expression. BMP-7–C4-2 cells and con-
trol pcDNA–C4-2 cell take rates were both 100%. Similar to in vitro
results, BMP-7–C4-2 TuV was not significantly different when com-
pared with the pcDNA–C4-2 tumors (Figure 7A), whereas serum
PSA levels in mice with BMP-7–C4-2 tumors were significantly
lower versus those with pcDNA–C4-2 (P = .0334; Figure 7B).
The PSA index at sacrifice (ng/ml PSA per mm3 of tumor) was also
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lower in the BMP-7–C4-2 group (43.9 ± 5.9% of the control, P =
.0023). Real-time PCR confirmed that high BMP-7 expression was
maintained in the BMP-7–C4-2 cells under in vivo conditions (data
not shown).
Tumors in the bone environment. Expression of BMP-7 did not
alter take rates of the tumor cells in the tibiae (100% in both groups).
To investigate the effects of BMP-7 expression on C4-2 tumor
growth in the bone, we performed BHM analysis. BMP-7 expression
significantly decreased BMP-7–C4-2 TuV versus pcDNA–C4-2 TuV
(0.40 ± 0.05 vs 0.61 ± 6.9 mm2, P = .033), and the tissue volume (TV)
of tibiae bearing BMP-7–C4-2 versus pcDNA–C4-2 tibiae (0.56 ±
7.3 vs 0.78 ± 4.8 mm2, P = .031). In contrast, no significant effects
on bone were detected: BVs of the tibiae with tumor were not different
Figure 5. There is a reciprocal relation between AR and Wnt promoter activity in PCa epithelial cells. (A) Luciferase assays to determine
the effect of DHT on AR (ARE) and Wnt signaling (TOPflash) in LNCaP cells. (B) Luciferase assays to determine if the AR inhibits TOP-
flash activity in PC-3 cells and if increasing doses of β-cat plasmid DNA alter AR inhibition of TOPflash activity in PC-3 cells. (C) Luciferase
assays to determine if AR inhibition (siRNA) influences TOPflash activity in LNCaP cells in the presence or absence of β-cat and if AR
inhibition (AR siRNA) increases TOPflash activity in LNCaP cells with increasing doses of β-cat plasmid DNA (1 μg plasmid DNA). Results
are plotted as mean ± SEM.
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between the groups, and there were no significant differences in BMD
between the BMP-7–C4-2 and pcDNA–C4-2 tibiae (Figure 7D). Rep-
resentative examples of the intratibial tumors are shown in Figure 7E .
To further evaluate the effects of BMP-7 expression on C4-2 cells in
the bone microenvironment, we also measured serum PSA levels in an-
imals bearing intratibial tumors. The serumPSA levels were significantly
higher in the BMP-7–C4-2 group versus the control pcDNA–C4-2
group (P = .026) by day 56 after implantation (Figure 7C ).
Discussion
A better understanding of the mechanisms involved in PCa progres-
sion and changes in cellular signaling is important for the develop-
ment of effective treatments for this disease. A considerable number
studies investigated the role of the BMPs in the prostate, PCa in situ,
and PCa metastasis, but still no conclusions can be made about their
effects during disease progression.
In our studies, we focused on investigating the effects of BMP-7
during PCa progression. To demonstrate the clinical relevance of
BMP-7, we showed decreases in BMP-7 mRNA levels in PCa in
comparison to normal prostatic epithelium. These results are in con-
cordance with previously published results [4]. These results together
with our results showing inhibition of PCa cell proliferation suggest
that BMP-7 is involved in the regulation of proliferation of these cells,
and therefore, alteration in BMP-7 signaling is important for disease
progression. However, our results have also shown that despite the de-
creases in BMP-7 mRNA expression in primary PCa versusNP, BMP-7
mRNA levels are increased in CR versus AD PCa xenografts.
In our immunohistochemical analyses of BMP-7 in clinical sam-
ples, we observed no difference in BMP-7 protein expression in pri-
mary PCa versus NP. The discordance between the mRNA and
protein levels of BMP-7 in primary PCa versus NP is not unusual
and may relate to alterations in translational mechanisms in the cells
[52]. However, similar to our CRmodels, BMP-7 is expressed at higher
levels in CR PCametastases when compared with primary PCa and NP.
BMP-7 expression is regulated by androgens in normal prostate,
and therefore, one would expect decreased levels in PCa cells after
castration. However, it has been shown that levels of AR are increased
in some CR PCa tumors in comparison to AD tumors and that
intratumoral androgens are present at similar levels in AD and CR
tumors despite the decreases in serum levels of these hormones [53].
In agreement with these facts, we showed that CR PCa LuCaP
xenografts have higher levels of AR mRNA and the levels of AR cor-
related with BMP-7 expression. Therefore, we hypothesize that
BMP-7 expression is increased in CR tumors in response to higher
levels of AR and that cross talk between these two pathways would
have potential significance in PCa progression of AD and CR disease.
Our results showed that BMP-7 inhibits proliferation of AD, more
differentiated LNCaP cells but not the proliferation of CR PC-3
cells, similar to our previous results with BMP-2 and -4 [5]. We hy-
pothesized that the expression of AR and AR signaling might be the
Figure 6. Characterization of BMP-7 overexpressing C4-2 cells. (A) Expression of BMP-7 mRNA in BMP-7–C4-2 cells. (B) Western anal-
ysis for BMP-7 of medium (10× concentrated) from BMP-7–C4-2 and pcDNA–C4-2 cells. (C) Cell count to determine cell growth of
pcDNA–C4-2 and BMP-7–C4-2 cells in vitro. (D) PSA secretion in pcDNA–C4-2 and BMP-7–C4-2 cells in vitro. (E) Alkaline phosphatase
activity in osteoblasts treated with conditioned medium from pcDNA–C4-2 cells, BMP-7–C4-2 cells, or BMP-7 alone (500 ng). Results are
plotted as mean ± SEM. *Significant from pcDNA–C4-2.
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cause of the differential response of PCa cells to BMPs. Our data
showed that AR expression is needed in androgen-sensitive differen-
tiated LNCaP cells for BMP-7 inhibition of proliferation, whereas
AR expression by itself is not sufficient to result in the inhibition
of proliferation by BMP-7 in CR C4-2 and C4-2B PCa cells. There-
fore, the differential response of the AD and CR PCa cells, which
both express AR, to BMP-7 suggests that alteration in AR and
BMP signaling and cross talk take place during PCa progression.
In contrast to our results, it has been reported that the expression
of AR in PC-3 cells made these cells susceptible to growth inhibition
by Smad signaling [23], whereas parental PC-3 cells were not inhib-
ited. We do not have a firm explanation of the discordance between
these results, but it is possible that forced expression of AR in PC-3
cells does not recapitulate PCa disease progression in the same fash-
ion as the LNCaP/C4-2/C4-2B progression model.
A network of interactions between growth factors, Wnt, and AR sig-
naling pathwaysmay be responsible for the onset of the aggressive tumor
phenotype [54]. To understand the potential mechanistic differences in
Figure 7. Growth response of BMP-7 overexpressing subcutaneous and intratibial tumors in vivo. (A) Subcutaneous TuVs of pcDNA–C4-
2 and BMP-7–C4-2 tumors in SCID mice (n = 5 per group). (B) Serum PSA in animals with subcutaneous pcDNA–C4-2 and BMP-7–C4-2
tumors in SCID mice (n = 5 per group). (C) Serum PSA in animals with intratibial pcDNA–C4-2 and BMP-7–C4-2 tumors in SCID mice
(n = 10 per group). (D) BMD of control and tibiae with tumor of BMP-7–C4-2 and pcDNA–C4-2 tumors in SCID mice (n = 10 per group).
(E) Control (pcDNA–C4-2) and BMP-7–C4-2 intratibial tumors. Results are plotted as mean ± SEM. *Significance, P < .05.
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the action of BMP-7 in PCa progression from the AD to a CR pheno-
type, we examined the interactions between the BMP,Wnt, and AR sig-
naling pathways.
BMP-7 increased the recruitment of nuclear AR and increased
AR-mediated transcriptional activity in the more differentiated
LNCaP cells, whereas these effects were not observed in C4-2 cells.
Again, this demonstrates alteration in the cross talk between AR and
BMP signaling during PCa progression. These differential effects are
not due to differential BMP-7 signaling through SMAD1 because
SMAD1 is phosphorylated in both cell lines in the presence of
BMP-7. Whereas BMP-7 and SMAD1 can clearly increase AR activ-
ity and the expression of AR-regulated genes, BMP treatment de-
creased the association between β-cat/AR with a concomitant
increase in E-cadherin and membrane-associated β-cat in androgen-
sensitive LNCaP cells. This was not observed in the CR C4-2 cells,
suggesting that the loss of nuclear β-cat/AR complexes in the more dif-
ferentiated LNCaP cells may be the crucial step that determines the
differential response of LNCaP cells to BMP-7 treatment.
Further exploring the relation between the AR and Wnt signaling
pathways, we found a reciprocal relation between the AR and Wnt
(β-cat) signaling pathways in PCa cells with increases in ARE activity
and a reciprocal decrease in β-cat activity in response to androgens.
This underscores our preliminary experiments that show BMP-7 in-
creases AR activity and the expression of androgen-regulated genes
while decreasing Wnt-regulated genes in LNCaP cells. Therefore,
our results suggest that BMP-7 promotes AR activity and inhibits
β-cat activity in differentiated PCa cells.
We observed an increase in AR expression and androgen-regulated dif-
ferentiation-associated genes PSA and human kallikrein 2, a loss of Wnt-
regulated genes c-Myc and survivin, and the alteration of EMT-associated
genes E-cadherin and vimentin in BMP-7-stimulated LNCaP cells. This
demonstrates that BMP-7 is promoting the epithelial phenotype in the
LNCaP cells, promoting the secretory phenotype, decreasing prolifera-
tion, and inhibiting EMT. The more dedifferentiated C4-2 cells did
not exhibit these changes. These results suggest that interactions among
BMP-7, AR, and Wnt pathways can promote the epithelial phenotype
and that the cross talk between these signaling pathways is altered in ad-
vanced PCa cells resulting in loss of BMP-7 control of proliferation and
differentiation of these cells. Identifying the events that are altered in re-
sponse to BMP-7 signaling in LNCaP and C4-2 cells may provide puta-
tive targets that determine epithelial cell fate in prostate tumorigenesis.
The tumor microenvironment has considerable impact on tumor
growth and development. Therefore, to determine if the events we
observed in vitro take place in vivo, we investigated whether C4-2
cells are resistant to BMP-7 growth inhibition in vivo. Overexpression
of BMP-7 did not significantly alter the growth of subcutaneous C4-2
tumors, although accompanied by slight decreases in serum PSA levels.
In contrast to subcutaneous tumors, when BMP-7–C4-2 and pcDNA–
C4-2 cells were grown in the bone environment, expression of BMP-7
resulted in decreased tumor area and interestingly, increases in serum
PSA levels in animals bearing BMP-7–C4-2 tumors when compared
with pcDNA–C4-2 intratibial tumors. These results are similar to those
of Buijs et al. [9], who reported that administration of recombinant
BMP-7 did not affect the growth of orthotopically implanted PC-
3M–Pro4/Luc+ PCa cells in athymic mice. However, the growth of
micrometastatic deposits from human PC-3M–Pro4/luc+ PCa cells in
bone marrow was inhibited significantly. Collectively, these results
demonstrate that the bone/tumor microenvironment can alter re-
sponses of tumor cells to BMP-7. Whether this is due to the effect
of BMP-7 on the stroma with a reciprocal response from the stroma
on the tumor cells or the direct effect of the stroma in concert with
BMP-7 on the tumor cells remains to be elucidated.
We expected that the expression of BMP-7 would increase new
bone formation in the intratibial tumors, yet there were no significant
differences observed in BMD or BV. One possible explanation is that
the osteolytic factors produced by C4-2 cells may be sufficient to over-
ride BMP-7 osteogenic activity in this tumor type in vivo [30,55].
In conclusion, we have shown that BMP-7 protein is expressed at
higher levels in PCa bone and soft tissue metastasis when compared
with primary PCa and NP, supporting our hypothesis that BMP-7
signaling is relevant to clinical disease progression. Furthermore,
our data suggest that interactions among the BMPs, Wnt, and AR
signaling pathways are altered during PCa progression. Moreover,
we have demonstrated in vivo that the tumor microenvironment
can impact tumor growth in bone in response to BMP-7. Further
investigation of the effects of BMPs on PCa cells is warranted to de-
lineate the signal transduction network alterations in PCa cells.
These results demonstrate the critical need to consider the different
tumor/stromal microenvironments when investigating pathways rel-
evant to PCa metastatic progression.
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